Published in Mol Pharm on June 07, 2008
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
Applications of orthogonal "click" chemistries in the synthesis of functional soft materials. Chem Rev (2009) 2.28
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev (2010) 1.82
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol (2009) 1.21
Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl (2010) 1.19
Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules (2010) 1.12
Multimodality Imaging of Integrin α(v)β(3) Expression. Theranostics (2011) 1.10
PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem (2009) 1.08
An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. Mol Pharm (2010) 1.03
A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials (2010) 1.02
Integrin Targeted MR Imaging. Theranostics (2011) 1.00
Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology (2013) 0.97
Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine (2013) 0.90
Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Mol Pharm (2011) 0.90
Intercepting the synthesis of triazine dendrimers with nucleophilic pharmacophores: a general strategy toward drug delivery vehicles. Chem Commun (Camb) (2009) 0.88
Bimodal imaging probes for combined PET and OI: recent developments and future directions for hybrid agent development. Biomed Res Int (2014) 0.88
Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm (2009) 0.88
Fluorescence imaging agents in cancerology. Radiol Oncol (2010) 0.87
Engineering nanomedicines for improved melanoma therapy: progress and promises. Nanomedicine (Lond) (2010) 0.85
Integrin targeted delivery of gene therapeutics. Theranostics (2011) 0.85
Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev (2011) 0.85
Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin. Chembiochem (2012) 0.83
Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. Interface Focus (2012) 0.82
Antimicrobial activity of CdS and Ag2S quantum dots immobilized on poly(amidoamine) grafted carbon nanotubes. Colloids Surf B Biointerfaces (2012) 0.82
Gd(3+)-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic-2-hydroxypropyl-β-cyclodextrin/Pluronic Polyrotaxane as a Long Circulating High Relaxivity MRI Contrast Agent. ACS Appl Mater Interfaces (2015) 0.80
Macrocyclic chelator assembled RGD multimers for tumor targeting. Bioorg Med Chem Lett (2011) 0.80
Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. BMC Pharmacol (2011) 0.79
A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells. Int J Nanomedicine (2013) 0.78
Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J Nanomedicine (2010) 0.78
cRGD peptide-conjugated icosahedral closo-B12(2-) core carrying multiple Gd3+-DOTA chelates for α(v)β3 integrin-targeted tumor imaging (MRI). Inorg Chem (2013) 0.78
Strategies for the preparation of bifunctional gadolinium(III) chelators. Curr Org Synth (2011) 0.78
Dendritic Guanidines as Efficient Analogues of Cell Penetrating Peptides. Pharmaceuticals (Basel) (2010) 0.77
Preparation, purification, and characterization of lanthanide complexes for use as contrast agents for magnetic resonance imaging. J Vis Exp (2011) 0.76
Molecular platform for design and synthesis of targeted dual-modality imaging probes. Bioconjug Chem (2015) 0.76
Human in vitro suppression as screening tool for the recognition of an early state of immune imbalance. J Vis Exp (2011) 0.75
Multifunctional drug nanocarriers formed by cRGD-conjugated βCD-PAMAM-PEG for targeted cancer therapy. Colloids Surf B Biointerfaces (2015) 0.75
Designing dendrimers for biological applications. Nat Biotechnol (2005) 4.92
Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem (1987) 4.87
Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation (2003) 3.15
Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev (2005) 2.33
Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med (2005) 2.09
Dendrimers in drug research. Chem Soc Rev (2003) 2.09
Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med (1994) 1.86
VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A (2005) 1.84
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem (2003) 1.67
Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res (1999) 1.66
Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb) (2005) 1.58
Synthesis and damage specificity of a novel probe for the detection of abasic sites in DNA. Biochemistry (1993) 1.52
3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med (2001) 1.49
Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res (2002) 1.47
Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjug Chem (1992) 1.44
Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc (2004) 1.32
Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA (2001) 1.22
The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed Engl (2002) 1.17
RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways. Lab Invest (2001) 1.17
Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood (1992) 1.17
Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci U S A (1998) 1.15
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry. J Med Chem (2007) 1.12
PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm (2005) 1.09
Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide. J Med Chem (2006) 1.07
Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med (2005) 1.02
Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol Cancer Ther (2003) 1.00
Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins. Bioconjug Chem (2007) 0.97
Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol (2006) 0.96
Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med (2000) 0.88
Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3). Q J Nucl Med (2003) 0.86
Purification of p-nitrobenzyl C-functionalized diethylenetriamine pentaacetic acids for clinical applications using anion-exchange chromatography. J Chromatogr A (1997) 0.86
Synthesis of branched oxime-linked peptide mimetics of the MUC1 containing a universal T-helper epitope. Chemistry (2004) 0.78
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov (2004) 2.73
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem (2009) 1.98
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev (2010) 1.82
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem (2003) 1.67
Radiologic manifestations of Proteus syndrome. Radiographics (2004) 1.66
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res (2002) 1.64
A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res (2007) 1.64
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging (2003) 1.49
Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg (2003) 1.48
Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm (2005) 1.48
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc (2007) 1.46
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol (2007) 1.44
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol (2007) 1.43
Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res (2003) 1.43
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum (2009) 1.42
Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm (2009) 1.42
Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol (2004) 1.40
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology (2013) 1.39